Since the Novo Nordisk (CSE: NOVOb) share price peaked in June last year just above the DKK 1,000 mark, it has suffered a severe setback and has now fallen by over 40%. In Decembe ...

Analysts predict the weight loss drug market to grow between $100 billion and $130 billion by 2030, as per a report.

The Food and Drug Administration has approved Ozempic ® (semaglutide) to reduce the risk of sustained estimated glomerular ...

As founder of Coatue Management, Philippe Laffont oversees $26.9 billion invested in more than 80 stocks, and though he buys ...

HonorHealth announced the creation of its new international Center for Translational Science. Sanofi said it will repurchase $5.2 billion of stock and grow profits faster this year as the drugmaker ...

The ClearBridge Large Cap Growth ESG Strategy underperformed its Russell 1000 Growth Index benchmark in the fourth quarter.

The results highlight an important physiological function of PGAM in the differentiation and suppressive activity of Treg cells by regulating serine synthesis. This role is proposed to intersect with ...

Novo Nordisk has asked the FDA to stop compounding pharmacies making cheaper versions of its semaglutide-based therapies for obesity and diabetes, saying the drug is too complex to be made safely ...

Along with NASH, Novo Nordisk is also planning to investigate the drug's activity in chronic kidney ... with preclinical-stage candidate IC 100 that is being considered for multiple sclerosis.

Anti-obesity drug Mounjaro is set to rack up global sales worth nearly £22bn a year by the end of the decade. But Donald ...